Skip to content

ImmunityBio, Inc. IBRX Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$0-100%
Amgen logo
AmgenAMGN
$3.96B
Moderna logo
ModernaMRNA
$150M
Eli Lilly logo
Eli LillyLLY
$0-100%
TG Therapeutics logo
TG TherapeuticsTGTX
$747.66M
AbbVie logo
AbbVieABBV
$7.99B+100%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromShortTermDebt.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s debt issuance proceeds?
ImmunityBio, Inc. (IBRX) reported debt issuance proceeds of $61K in Q1 2026.
What does debt issuance proceeds mean?
Cash received from taking on new debt.
How do you interpret debt issuance proceeds?
Higher inflows provide immediate liquidity but increase future interest obligations and leverage risk.
How does debt issuance proceeds compare across companies?
Used by companies to manage liquidity needs when equity financing is undesirable or unavailable.